Technical Analysis Perspective: Amedisys, Inc. (AMED), Immunomedics, Inc. (IMMU)

Cornelia Mascio
Agosto 18, 2017

In recent action, Immunomedics, Inc. (NASDAQ:IMMU) by 7.8% during the second quarter, according to its most recent 13F filing with the SEC. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The NYSE listed company saw a recent bid of 83.67 and 3630321 shares have traded hands in the session. Atlantic Trust Group LLC acquired a new stake in shares of Immunomedics during the first quarter worth $599,000. During the same period previous year, the firm posted ($0.17) earnings per share. Manufacturers Life Insurance The holds 0% in Immunomedics, Inc. The company's institutional ownership is monitored at 96.7 percent.

Sabby Management Llc increased Redhill Biopharma Ltd (NASDAQ:RDHL) stake by 127,985 shares to 191,785 valued at $2.01M in 2016Q4.

Shares of Immunomedics, Inc. Given that liquidity is king in short-term, AMED is a stock with 33.41 million shares outstanding that normally trades 8.23% of its float. Immunomedics has a 52-week low of $2.02 and a 52-week high of $9.51. Noting its average daily volume at 2.08 million shares each day over the month, this signifies a pretty significant change over the norm. The company's 50 day moving average is $8.55 and its 200 day moving average is $6.87. (IMMU) now trades with a market capitalization of $879.66 Million.

Many analysts are providing their Estimated Earnings analysis for Immunomedics Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.12/share.

The company has mean EPS estimate of -0.12 reported by 3 number of analyst for the quarter ending Current Qtr.(Sep2017). The difference between the expected and actual EPS was $-0.42/share, which represents an Earnings surprise of -323.1%. The company had revenue of $0.64 million during the quarter, compared to analysts' expectations of $0.75 million. For IMMU, the company now has $21.9 Million of cash on the books.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was copied illegally and reposted in violation of USA and global trademark & copyright laws. The correct version of this news story can be accessed at (NASDAQ:IMMU). Orbimed Advisors Lc reported 0.18% stake. Finally, Cowen and Company began coverage on shares of Immunomedics in a research report on Friday, May 26th. Jefferies downgraded the stock to "Hold" rating in Wednesday, July 29 report. Wells Fargo & Company upgraded shares of Immunomedics from a "market perform" rating to an "outperform" rating in a research report on Friday, May 5th. BidaskClub cut Immunomedics from a "buy" rating to a "hold" rating in a report on Friday, August 4th.

A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company.

Analysts are speculating a 17.74% move, based on the high target price ($60) for the shares that is set to reach in the next 12 months.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE